ZLB buys MedImmune's CytoGam for $50M
US drugmaker MedImmune says it has completed the sale of the organ transplant drug CytoGam (cytomegalovirus immune globulin intravenous (human)) to ZLB Behring, a part of the Australian CSL group. The product is approved for the prophylactic treatment and prevention of CMV infection during transplant surgery.
Under the terms of the deal, which was originally executed late last year (Marketletter November 13, 2006), ZLB made an initial upfront payment of $50.0 million, plus costs for equipment and inventory, in exchange for worldwide rights to the drug. The agreement also stipulates that ZLB pays a further $70.0 million to the Gaithersburg-headquartered firm when certain cumulative, net sales milestones are achieved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze